Introduction
The molecular mechanisms by which chemotherapeutic agents kill tumor cells are numerous and dependent on a variety of parameters including the drug and tumor types. Advances in defining the connection between chemotherapeutic drug action and alteration in cell death signaling have demonstrated that agents such as doxorubicin, methotrexate, cytarabine, etoposide and cisplatin induce apoptosis via the p53/Fas/Caspase-8 system (Friesen et al., 1996 (Friesen et al., , 1997 (Friesen et al., , 1999 . These drugs stimulate transcriptional activity of the proapoptotic molecule p53, which induces expression of the death ligand (Fas L) leading to activation of the Fas receptor. Activated Fas receptor binds, via its cytosolic domain, to adapter proteins such as the Fas-associated death domain (FADD) and the apoptosis initiator, caspase-8 (Cohen et al., 1997) . Activated caspase-8 cleaves Bid (Li et al., 1998; Kim et al., 2000) , producing truncated Bid, which interacts with mitochondria to cause the release of cytochrome c. The latter activates caspase-9, transmitting apoptotic signals to the nucleus through downstream targets such as caspase-3 and endonucleases, ultimately causing DNA fragmentation and cell death (Cohen et al., 1997) .
Altered cell susceptibility to commit to apoptosis following drug treatment is believed to be among the mechanisms that contribute to the genesis of acquired drug resistance (Zunino et al., 1997; Kojima et al., 1998) . While this phenomenon has been demonstrated in malignancies of lymphoid origin (Lowe et al., 1993; Brown and Wouters, 1999) , it was not applicable for other solid tumors where apoptosis seems to have little or no influence on chemotherapy outcome (Brown and Wouters, 1999; Borst et al., 2001; Roninson et al., 2001; Roninson, 2002) . These studies have shown that while activation of apoptosis is associated with cell death, its inhibition did not correlate with cell survival. To understand the role of apoptosis in cell response to chemotherapy, it becomes critical to determine which type of death prevails when apoptosis is prevented from occurring.
A variety of caspase inhibitors have been developed and used as valuable tools to study the mechanism of action of these enzymes, and to define the role of apoptosis in drug-induced cell death. While most of these agents were very efficient in inhibiting caspase activation and apoptotic features, they did not protect cells from the cytotoxic action of drugs. In fact, a switch from apoptotic to nonapoptotic cell death was frequently observed when caspase inhibitors were combined with apoptosis-inducing agents (Luschen et al., 2000; Hartmann et al., 2001; Kim and Han, 2001; Martinsson et al., 2001; Yaginuma et al., 2001) .
Evidence is accumulating that cytotoxic drugs, particularly at subapoptotic concentrations, can induce terminal growth arrest with features of senescence. p53 and the CDK inhibitor p21/WAF1 are major players in this process (Chang et al., 2002; Han et al., 2002; te Poele et al., 2002) . The role of senescence as a determinant of chemotherapy outcome is poorly documented, perhaps because it has been overshadowed by the high interest in apoptosis. It has been reported that expression of the senescence-associated protein p21/ WAF1 correlates with improved survival after chemotherapy treatment in pancreatic cancer (Ahrendt et al., 2000) , esophageal carcinoma (Nakashima et al., 2000) , head and neck (Kapranos et al., 2001 ) and ovarian cancer (Ferrandina et al., 2000) . In addition, recent findings suggest that senescence may play a key role in chemotherapy outcome (Roninson, 2002; Schmitt et al., 2002; te Poele et al., 2002) . This, in comparison with the fact that the ability of tumor cell to undergo apoptosis may not play a key role in sensitivity to DNA-damaging agents (Brown and Wouters, 1999) , suggests that senescence, rather than apoptosis, may take place in determining the outcome of chemotherapeutic interventions.
Since senescence can be triggered by much lower stress levels than apoptosis, if the latter is inhibited, the former may still occur. The present investigation has addressed this possibility by identifying the different modes of cell death induced by doxorubicin, particularly as they relate to drug concentration and duration of exposure. These findings were then utilized to explain the switch of cell death mode that results from inhibition of apoptosis.
Results

Modes of cell death induced by doxorubicin
The human neuroblastoma cell line SKN-SH was used to identify and characterize the different types of cells death induced by doxorubicin. We have shown previously that these cells can readily undergo apoptosis when incubated with doxorubicin . In the present study, we have found that cell exposure to low (10 À7 m), medium (10 À6 m) and high (10 À5 m) concentrations of doxorubicin induced different morphological features that were distinguished by phase microscopy after 24 h of treatment (Figure 1a ). In the presence of a low drug concentration (10 À7 m), the major morphological change observed was a flattening of cells. This was accompanied by a slight induction of apoptosis as judged by DNA fragmentation (Figure 1c ). Cell treatment with 10 À6 m doxorubicin elicited a more differentiated phenotype characterized by neurite extension and cytoplasmic shrinkage (Figure 1a (Figure 1a) . The cytoplasmic volume was markedly diminished and the nucleus to cytoplasm ratio increased. Surprisingly, both caspase-3 activation and DNA fragmentation were abrogated at this concentration (Figure 1b and c) . Expression of caspase-3 proform was not altered (Figure 1b) , suggesting that an antiapoptotic pathway was activated under these conditions.
While the onset of cell death by 10 À6 and 10 À5 m was very rapid (after 2 days nearly all cells died, data not shown), cells treated with doxorubicin at 10 À7 m expressed irreversible growth arrest with typical features of senescence. Senescence-associated -b-galactosidase (SA-b-gal) staining after 5 days of incubation with doxorubicin confirmed that these cells had acquired a senescent phenotype (Figure 1d ). These data indicate that doxorubicin can induce at least three types of cell death in SKN-SH cells that appear to be directly dependent on drug concentration and duration of exposure.
Molecular events associated with each mode of cell death induced by doxorubicin
Optimal detection of SA-b-Gal necessitates at least 5 days of incubation with doxorubicin (10 À7 m). However, most cells died when incubated with 10 À6 or 10 À5 m doxorubicin for periods greater than 48 h. In order to elucidate putative switches between these cell death modes, it was critical to identify the early molecular changes that occurred prior to 48 h. As a candidate molecule for investigation, the cell cycle inhibitor p21/ WAF1 was selected because it was found to be associated with doxorubicin-induced senescence (Roninson et al., 2001 ) and can be induced by this drug within 24 h. In addition, cleaved (activated) caspase-3, an apoptosis marker inducible within 24 h (Cohen, 1997; Rebbaa et al., 2001 ) was also selected. These two molecules were sought to be suitable determinants to study the switch between senescence and apoptosis. Also, since apoptosis was inhibited at high doxorubicin concentration (Figure 1) , we investigated the possible activation of an anti-apoptotic molecule, phosphorylated Akt (p-Akt) (Zhou et al., 2000; Brognard et al., 2001; Emran et al., 2001 ) under these conditions. SKN-SH cells were treated with varying doxorubicin concentrations for 24 h, and the expression of p21/ WAF1, caspase-3 and p-Akt determined by Western blot (Figure 2 ). The expression of p21/WAF1 was maximal at 10 À7 m doxorubicin, followed by a sharp decrease at 10 À6 m and complete disappearance at 10 À5 m. While expression of this molecule at the low concentration of doxorubicin (10 À7 m) was anticipated and confirmed the senescence phenotype, its rapid decay at higher drug concentrations (10 À6 -10 À5 m) was not and suggested that p21/WAF1 might play a key role in the switch from senescence to other death modes.
In a manner paralleling that of p21/WAF1, the activation pattern of caspase-3 also consisted of a peak followed by a sharp decrease. Maximum expression of caspase-3 occurred at 10 À6 m doxorubicin ( Figure 2 ) and supported the DNA fragmentation data (Figure 1b) .
Interestingly, increased caspase-3 activation correlated with decreased p21/WAF1 expression. This inverse relation suggests that the former might degrade the latter, which may trigger the switch from senescence to apoptosis. In support of this hypothesis, p21/WAF1 has been shown to be a substrate for caspase-3 (Jin et al., 2000) . Whereas, the disappearance of both caspase-3 and p21 expression at 10 À5 m doxorubicin (Figure 2 ) indicated that a caspase-independent pathway might be responsible for inhibiting p21/WAF1 expression, at least at this concentration.
We made the hypothesis that inhibition of caspase-3 at high doxorubicin concentrations may result from activation of an antiapoptotic pathway. A likely candidate molecule is Akt, which is widely known for its implication in cellular defense and inhibition of apoptosis (Brognard et al., 2001) . The appearance of P-Akt in response to doxorubicin treatment in SKN-SH cells followed a pattern indicative of maximum expression at 10 À5 m doxorubicin, which correlated with Senescence as a result of apoptosis inhibition A Rebbaa et al decreased caspase-3 activity. This also suggests that phosphorylation of Akt could be associated with the mode of cell death observed at high doxorubicin concentration.
Effect of doxorubicin on human glioma cell lines
In order to determine if the differential effect of doxorubicin on cell death pathways was a generalized phenomenon, parallel investigation was performed using two glioma cell lines (U87 and U251). When these cells were incubated under the same conditions utilized for SKN-SH cells (Figure 2) , a dose-dependent increase in p21/WAF1 expression was observed in both U87 and U251cells (Figure 3a and b, respectively), followed by a sharp decrease at 10 À5 m doxorubicin. Curiously, p21/ WAF1 appeared to be expressed as a doublet in U251 cells (Figure 3b ) and only the lower band decreased at high drug concentration.
The activation of caspase-3 in U87 and U251 cells in response to doxorubicin also followed a pattern similar to that of SKN-SH cells, however, the inverse relationship between expression of p21/WAF1 and activation of caspase-3 was less evident in U251 cells (Figure 3b ). This may constitute an argument against the possibility of p21/WAF1 degradation by caspase-3. One additional difference between these glioma cell lines and the neuroblastoma cells is that caspase-3 activation was not sharply decreased at 10 À5 m doxorubicin, nor was Akt activated at this concentration. These observations infer that activation of Akt and inhibition of caspase-3 activity may occur in U87 and U251 cell lines at a drug concentration higher than 10 À5 m. Indeed, Figure 3c reveals that in cells treated with 10 À4 m doxorubicin, Akt phosphorylation increased and caspase-3 activation decreased.
Relation between caspase inhibition and doxorubicin toxicity
The effect of pan-caspase inhibitors (Z-vad-fmk and Q-VD-OPH) on caspase-3 activation and cell death in SKN-SH cells was determined. After incubation with doxorubicin at the apoptotic concentration (10 À6 m) for 24 h, cleaved caspase-3 was detected by Western blot. As shown in Figure 4a , Z-vad-fmk did not inhibit caspase-3, instead, it appeared to induce more cleavage of this enzyme. The reason for this is unknown, although, this phenomenon has been observed in other cells lines (Kim and Han, 2001) . Significantly, the irreversible caspase inhibitor, Q-VD-OPH, induced a marked inhibition of caspase-3 (Figure 4a ).
To determine whether the difference in potency between these caspase-3 inhibitors provided differential protection against doxorubicin-mediated cell death, SKN-SH cells were treated with each inhibitor in the presence and the absence of doxorubicin 10 À6 m (Figure 4b ). The data revealed that cell death was similar in cells treated with doxorubicin alone or when combined with either caspase inhibitor. Although Q-VD-OPH inhibited caspase-3, it did not provide SKN-SH cells with a survival advantage.
Effects of Q-VD-OPH/doxorubicin on expression of molecular determinants of cell death in SKN-SH cells
Morphologic analyses of cells treated for 24 h with either doxorubicin (10 À6 m), Q-VD-OPH (20 mm) or a combination of both agents (Figure 5a ) were performed. Cells treated with doxorubicin alone displayed a typical apoptotic phenotype characterized by plasma membrane blebbing and the appearance of apoptotic bodies. In contrast, most of the cells treated with the combination of doxorubicin and Q-VD-OPH became round and did not display any signs of apoptosis. Those treated with Q-VD-OPH alone were morphologically identical to the nontreated cells.
Analysis of p21/WAF1 expression showed that only traces of this protein were detected in the presence of 10 À6 m doxorubicin (Figure 5b ), which concurs with data , and Western blot analyses for expression of p21/WAF1, cleaved caspase-3, phosphorylated Akt and b-actin were performed using specific antibodies. Doxorubicin (10 À4 m) was used to illustrate activation of Akt (P-Akt) and decreased caspase-3 activation (Cl. Casp-3) in both U87 and U251 cells (panel c). bActin was used as a loading control
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A Rebbaa et al presented in Figure 2 . Q-VD-OPH by itself had no effect on p21/WAF1 expression. However, co-treatment with doxorubicin and Q-VD-OPH had significantly higher levels of p21/WAF1 protein expressed, when compared to the individual effects of each drug on these cells. This finding suggests that caspase inhibition could switch cell death from apoptosis to senescence. To further validate this observation, the effect of Q-VD-OPH on SA-b galactosidase staining was investigated. SKN-SH cells incubated with and without the individual drugs did not display any sign of SA-bgalactosidase staining (Figure 5c ), whereas cells treated with the drug combination showed intense staining. Collectively, these data suggest that inhibition of apoptosis may not protect SKN-SH cells from doxorubicin toxicity, because it switches drug-induced cell death to senescence.
Discussion
The concept that tumor cells exposed to cytotoxic drugs die from apoptosis has become so widely accepted and the presumption has been made that inhibition of this process would protect cancer cells from the effects of chemotherapy. Data presented in this study provide a - Senescence as a result of apoptosis inhibition A Rebbaa et al molecular explanation for the fact that inhibition of apoptosis alone may not be sufficient for tumor cell survival in a cytotoxic environment. We suggest that caspase inhibition results in enhanced expression of cell cycle regulators, leading to a permanent growth arrest with features very compatible to those of senescence.
The possible modes of cell death induced by doxorubicin and associated molecular determinants have been investigated. This drug was found to induce at least three different types of cell death in neuroblastoma cells, SKN-SH (Figure 1 ). Initially, 1 or 2 days following incubation with doxorubicin, only cells treated with medium (10 À6 m) and high (10 À5 m) drug concentrations appeared to be engaged in a cell death process. In fact, cells treated with lower drug concentration (10 À7 m) acquired features of a senescence phenotype (Figures 1d and Figure 2) followed by a delayed death. Molecular characterization of these three cell death modes (Figure 2 ) confirmed at least the first two as senescence and apoptosis as evidenced by the expression of SA-b-gal, p21/WAF1 and activation of caspase-3. The third type of cell death could be of a necrotic type based on its morphological characteristics, that is, nuclear chromatin decondensation and cytoplasmic shrinkage, possibly because of increased plasma membrane leakage. Increased phosphorylation of Akt (PAkt) was also associated with this type of death (Figure 2 ). In light of the well-described antiapoptotic function of Akt, the correlation between decrease in activated caspase-3 and increase in Akt activation (Figures 2 and 3) suggests that Akt may exert its antiapoptotic function upstream of caspase-3. Indeed, two major sites of Akt action, inhibition of Bax and caspase-9 (Zhou et al., 2000) have been described as occurring upstream of caspase-3. Activation of Akt in conditions where caspase-3 is inhibited was expected, but since SKN-SH cells die at this high drug concentration, Akt activation does not appear to serve as a mechanism for preventing drug toxicity. It seems that this pathway becomes activated only in circumstances of severe cellular injury, and its role in cell rescue under such conditions is not clear.
Findings from our study of cell killing by doxorubicin (Figures 1-3 ) led to the identification of three major modes of cell death with a possible overlap between two contiguous death modes. With apoptosis located in the middle (in term of stress level) between senescence and the necrotic type of cell death, inhibition of apoptosis alone may not result in cell survival. The identification of p21/WAF1, caspase-3 and P-Akt as determinants associated with these cell death modes was utilized subsequently in this study to characterize the default death that accompany inhibition of apoptosis.
The response of the neuroblastoma cell line, SKN-SH, to the combination of caspase inhibitor and doxorubicin (Figure 4) confirmed the hypothesis that inhibition of apoptosis does not necessarily protect cells from death by anticancer agents. The key finding however is that under such conditions, cell death is switched from apoptosis to senescence ( Figure 5 ) as illustrated by the induction of p21/WAF1 and SA-b-gal expression only in cells treated with the drug combination. These observations suggest that senescence and apoptosis may compete with each other in an exclusive way. This phenomenon is illustrated in Figures 2 and 3 , where the increased expression of p21/WAF1 is accompanied by a decrease in caspase-3 activation and vice versa.
Since senescence occurs at a subapoptotic concentration, it is likely that at apoptotic drug concentration (10 À6 m for SKN-SH), cells are susceptible to both senescence and apoptosis. However, these two processes may not occur concurrently, since the apoptotic machinery may degrade specific cell cycle regulators and dominate over the senescence pathway. In this circumstance, senescence can proceed only if apoptosis is inhibited.
Senescence is viewed as a 'fail safe' mode used by eucaryotic cells to exit cell cycle activation mediated by oncogenes such as ras (Serrano et al., 1997) . Therefore, this process has been considered as a tumor suppressor program. In light of this, our findings suggest that development of molecules to regulate senescence could be a feasible therapeutic approach for the prevention and/or treatment of cancer. A recent study by Schmitt et al. (2002) using murine models highlighted the relevance of senescence, rather than apoptosis in determining the outcome of chemotherapeutic interventions. Our findings are not only in agreement with this theory, but also provide a molecular basis for its validity.
Materials and methods
Reagents
The following materials were obtained from the companies cited: Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) (BioWhittaker, Walkersville, MD, USA); doxorubicin, 3-(4,5-dimethyl-2-thiazolyl)2,5-diphenyl tetrazolium bromide (MTT) (Sigma, St Louis, MO, USA); Q-VD-OPH (Enzyme Systems Products, Inc., Livermore, CA, USA), X-Gal, agarose gel (Sigma, St Louis, MO, USA); antibodies to p21/WAF1, to b-actin (Santa Cruz Biotechnologies, CA, USA); to phospho-Akt, to caspase-3, cleaved caspase-3 and secondary antibodies conjugated to horseradish peroxidase (Cell Signaling Technologies, Beverly, MA, USA); enhanced chemiluminescence reagents (ECL) (Amersham, Arlington Heights, IL, USA); Immobilon-P transfer membrane for western blot (Millipore, Bedford, MA, USA).
Cell culture, drug treatment and cytotoxicity assay
Human neuroblastoma cells (SKN-SH) and glioma cell lines (U87 and U251) were obtained from the American Type Culture Collection. The cells were grown in DMEM supplemented with 10% FBS at 371C in a 95% Air/5%CO 2 atmosphere. The cytotoxic activity of doxorubicin and Q-VD-OPH were quantitatively determined by a colorimetric assay utilizing MTT, as described previously . Briefly, cells were seeded at 10 4 cells/well in 96-well plates and maintained in culture for 24 h at 371C in DMEM supplemented with 10% FBS. Drugs were added to designated wells and cells incubated for 8 days following which MTT (10 ml of 5 mg/ml solution) was added to each well (100 ml) and incubated for 4 h at 371C. The cells were solubilized by incubation with 100 ml of HCl 0.5 n/isopropanol for 15 h at 371C. The optical density of this solution was measured at 570 nm and the percentage of viable cells estimated by comparison with untreated control cells.
Western blot analysis
Cells were seeded in 25 cm 2 flasks in DMEM containing 10% FBS and cultivated for 24 h before the addition of doxorubicin and/or Q-VD-OPH and incubated for an additional 24 h. Proteins were then solubilized with lysis buffer (50 mm HEPES pH 7.4, 150 mm NaCl, 100 mm NaF, 1 mm MgCl 2 , 1.5 mm EGTA, 10% glycerol, 1% Triton X-100, 1 mg/ml leupeptin, 1 mm phenyl-methyl-sulfonyl-fluoride). Equal quantities of protein were separated by electrophoresis on a 12% SDS-PAGE gel and transferred on to Immobilon-P membranes. Proteins of interest were identified by reaction with specific primary and secondary antibodies linked to horseradish peroxidase. Reactive bands were detected by chemiluminescence.
SA-b-gal staining
Cells were seeded into 24-well plates in DMEM culture medium and after 24 h, doxorubicin was added at 10 À7 m. The cells were incubated for 5 days. SA-b-gal staining was performed as previously described (Dimri et al., 1995) . In brief, cells were fixed for 5 min in 3% formaldehyde, washed and incubated at 371C with X-gal (1 mg/ml), dissolved in a solution containing 40 mm citric acid pH 6.5, 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, 150 mm NaCl and 2 mm MgCl 2 . After 24 h incubation, photographs were taken under phase microscope.
Measure of DNA fragmentation
Cells were incubated with doxorubicin at various concentrations for 24 h at 371C and DNA prepared from Triton X-100 lysates for analysis of fragmentation. Briefly, cells were lysed in hypotonic solution containing 10 mm Tris-HCl (pH 7.4), 1 mm EDTA and 0.2% Triton X-100 and centrifuged at 11 000 Â g for 5 min. Supernatants were electrophoresed on a 1% agarose gel and the DNA fragments visualized by UV light after staining with ethidium bromide.
